Canadian gene therapy biotech enGene starts trading on Nasdaq after completing Forbion SPAC deal
Gene therapy startup enGene became a public biotech on Wednesday after completing its combination with Forbion European Acquisition, a blank check company
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
